Advanced search
Publication Cover
OncoImmunology Volume 10, 2021 - Issue 1
Submit an article Journal homepage
2,322
Views
2
CrossRef citations to date
0
Altmetric
Author’s View

Low-dose HDACi potentiates anti-tumor activity of macrophages in immunotherapy

Xiaolei LiDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2697-6496
ORCID Icon,
Hanren DaiDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaORCID Iconhttps://orcid.org/0000-0001-7662-511X
ORCID Icon &
Hua WangDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2605-5697
ORCID Icon
Article: 1935668 | Received 20 May 2021, Accepted 25 May 2021, Published online: 06 Jun 2021

References

  • Li X, Shao C, Shi Y, Han W. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol. 2018;11:31.
  • Wang Y, Chen M, Wu Z, Tong C, Dai H, Guo Y, Liu Y, Huang J, Lv H, Luo C, et al. CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial. Oncoimmunology. 2018;7(7):e1440169. doi:10.1080/2162402X.2018.1440169.
  • Dai H, Zhang W, Li X, Han Q, Guo Y, Zhang Y, Wang Y, Wang C, Shi F, Zhang Y, et al. Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology. 2015;4(11):e1027469. doi:10.1080/2162402X.2015.1027469.
  • Li X, Song W, Shao C, Shi Y, Han W. Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. Cell Mol Immunol. 2019;16:28–2. doi:10.1038/s41423-018-0086-z.
  • Demaria O, Cornen S, Daeron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574:45–56. doi:10.1038/s41586-019-1593-5.
  • Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell. 2014;54:716–727. doi:10.1016/j.molcel.2014.05.015.
  • Pace L, Goudot C, Zueva E, Gueguen P, Burgdorf N, Waterfall JJ, Quivy J-P, Almouzni G, Amigorena S. The epigenetic control of stemness in CD8+T cell fate commitment. Science. 2018;359:177–186. doi:10.1126/science.aah6499.
  • Aspeslagh S, Morel D, Soria JC, Postel-Vinay S. Epigenetic modifiers as new immunomodulatory therapies in solid tumours. Ann Oncol. 2018;29:812–824. doi:10.1093/annonc/mdy050.
  • Cao K, Wang G, Li W, Zhang L, Wang R, Huang Y, Du L, Jiang J, Wu C, He X, et al. Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity. Oncogene. 2015;34(49):5960–5970. doi:10.1038/onc.2015.46.
  • Brogdon JL, Xu Y, Szabo SJ, An S, Buxton F, Cohen D, Huang Q. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood. 2007;109:1123–1130. doi:10.1182/blood-2006-04-019711.
  • Li X, Su X, Liu R, Pan Y, Fang J, Cao L, Feng C, Shang Q, Chen Y, Shao C, et al. HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression. Oncogene. 2021;40(10):1836–1850. doi:10.1038/s41388-020-01636-x.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.